BCA
MLYS icon

Buckley Capital Advisors’s Mineralys Therapeutics MLYS Stock Holding History

Buckley Capital Advisors’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-173,100
Closed -$4.69M – 16
2026
Q1 		$4.69M Sell
173,100
-1,200
-0.7% -$35.2K 3.37% 12
2025
Q4 		$6.33M Buy
+174,300
New +$6.99M 4.45% 11

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Buckley Capital Advisors's MLYS Position: Q2 2026 in Review

Buckley Capital Advisors sold out of Mineralys Therapeutics (MLYS) in Q2 2026, closing a stake of 173,100 shares — an estimated $4.69M sold.

Buckley Capital Advisors first reported a position in MLYS in Q4 2025 and held it in 2 quarters. The position peaked at $6.33M in Q4 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Buckley Capital Advisors reported no remaining Mineralys Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Buckley Capital Advisors sold 173,100 Mineralys Therapeutics shares in Q2 2026, an estimated $4.69M.
  • Buckley Capital Advisors first reported a position in Mineralys Therapeutics in Q4 2025 and held it in 2 quarters.
  • Buckley Capital Advisors's Mineralys Therapeutics position peaked at $6.33M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Buckley Capital Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.